Carcinogenesis Advance Access originally published online on January 20, 2005
Carcinogenesis 2005 26(4):785-791; doi:10.1093/carcin/bgi026
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Carcinogenesis vol.26 no.4 © Oxford University Press 2005; all rights reserved.
ARTICLE |
Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: a potential target for prevention
Departments of Clinical Cancer Prevention, 1 Pathology, 2 Thoracic and Cardiovascular Surgery and 3 Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX and 4 Department of Pathology, Anhui Medical University, Hefei, China
* To whom correspondence should be addressed. Tel: +713 745 2940; Fax: +713 563 5747; Email: xxu{at}mdanderson.org
Arachidonic acid (AA) is the major precursor of several classes of signal molecules and the alteration of its metabolism is involved in human carcinogenesis. For instance, 5-lipoxygenase (5-LOX) converts AA to hydroxyeicosatetraenoic acids or leukotrienes (LTs), which are able to enhance proliferation, increase survival and suppress the apoptosis of human cells. To determine the potential use of 5-LOX inhibitors in the prevention of esophageal cancer, we first analyzed the 5-LOX expression in esophageal tissue samples using immunohistochemistry and then examined the effect of the 5-LOX inhibitors AA861 and REV5901 on cell viability and apoptosis in esophageal cancer cell lines. 5-LOX expression was present in 79% (127/161) of esophageal cancer but in only 13% (4/32) of normal esophageal mucosa. 5-LOX was also expressed in all the eight esophageal cancer cell lines. Moreover, 5-LOX inhibitors caused a dose- and time-dependent reduction of cell viability, which was due to the induction of apoptosis and associated with LTB4 suppression. Our data also showed that both LTB4, a product of 5-LOX and LTB4 receptor antagonist U-75302 were able to prevent AA861 and REV5901 on induction of apoptosis. The present study demonstrated that 5-LOX protein expression is increased in esophageal cancer and that 5-LOX inhibitors can induce esophageal cancer cells to undergo apoptosis, suggesting that 5-LOX may be an effective target in the prevention of esophageal cancer.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
L. G. Melstrom, D. J. Bentrem, M. R. Salabat, T. J. Kennedy, X.-Z. Ding, M. Strouch, S. M. Rao, R. C. Witt, C. A. Ternent, M. S. Talamonti, et al. Overexpression of 5-Lipoxygenase in Colon Polyps and Cancer and the Effect of 5-LOX Inhibitors In vitro and in a Murine Model Clin. Cancer Res., October 15, 2008; 14(20): 6525 - 6530. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Sveinbjornsson, A. Rasmuson, N. Baryawno, M. Wan, I. Pettersen, F. Ponthan, A. Orrego, J. Z. Haeggstrom, J. I. Johnsen, and P. Kogner Expression of enzymes and receptors of the leukotriene pathway in human neuroblastoma promotes tumor survival and provides a target for therapy FASEB J, October 1, 2008; 22(10): 3525 - 3536. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Hoque, H. Chen, and X.-c. Xu Statin Induces Apoptosis and Cell Growth Arrest in Prostate Cancer Cells Cancer Epidemiol. Biomarkers Prev., January 1, 2008; 17(1): 88 - 94. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Peters-Golden and W. R. Henderson Jr. Leukotrienes N. Engl. J. Med., November 1, 2007; 357(18): 1841 - 1854. [Full Text] [PDF] |
||||
![]() |
Y. Torosyan, A. Dobi, S. Naga, K. Mezhevaya, M. Glasman, C. Norris, G. Jiang, G. Mueller, H. Pollard, and M. Srivastava Distinct Effects of Annexin A7 and p53 on Arachidonate Lipoxygenation in Prostate Cancer Cells Involve 5-Lipoxygenase Transcription Cancer Res., October 1, 2006; 66(19): 9609 - 9616. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Sun, S. Sood, N. Li, D. Ramji, P. Yang, R. A. Newman, C. S. Yang, and X. Chen Involvement of the 5-lipoxygenase/leukotriene A4 hydrolase pathway in 7,12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamster cheek pouch, and inhibition of carcinogenesis by its inhibitors Carcinogenesis, September 1, 2006; 27(9): 1902 - 1908. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Poole, J. Bigler, J. Whitton, J. G. Sibert, J. D. Potter, and C. M. Ulrich Prostacyclin synthase and arachidonate 5-lipoxygenase polymorphisms and risk of colorectal polyps. Cancer Epidemiol. Biomarkers Prev., March 1, 2006; 15(3): 502 - 508. [Abstract] [Full Text] [PDF] |
||||





